Regeneus

Regeneus

An Australian clinical stage regenerative medicine company founded in 2007 developing cellular therapies based on stem cells and stem cell secretions to treat osteoarthritis, cancer, skin conditions and chronic pain.

All edits

Edits on 23 Feb, 2021
Golden AI"Setting founded date to the company's date of incorporation."
Golden AI edited on 23 Feb, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
2007
Edits on 15 Feb, 2021
Golden AI
Golden AI edited on 15 Feb, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Founder
Graham Vesey
Golden AI
Golden AI edited on 15 Feb, 2021
Edits made to:
Infobox (+1 properties)
Infobox
CEO
Graham Vesey
Golden AI
Golden AI edited on 15 Feb, 2021
Edits made to:
Infobox (+1 properties)
Infobox
CEO
Karolis Rosickas
Edits on 19 Feb, 2020
Golden AI"Adding location topic from lookup Sydney, Australia"
Golden AI edited on 19 Feb, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Location
Australia
Edits on 19 Mar, 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 19 Mar, 2019
Edits made to:
Article (+8/-8 characters)
Article

The company's allogeneic stem cell technology platform for the treatment of osteoarthritis (OA) and other inflammatory conditions is called Progenza. Results of the phase 1 STEP trial (Safety, Tolerability and EfficacyEfficacy of Progenza) were published in the Journal of Translational Medicine in 2018.

Edits on 14 Mar, 2019
Dawson Sewell
Dawson Sewell edited on 14 Mar, 2019
Edits made to:
Infobox (+9 properties)
Article (+9/-9 characters)
Further reading (+3 rows) (+12 cells) (+695 characters)
Categories (+2 topics)
Article

The company's allogeneic stem cellstem cell technology platform for the treatment of osteoarthritis (OA) and other inflammatory conditions is called Progenza. Results of the phase 1 STEP trial (Safety, Tolerability and Efficacy of Progenza) were published in the Journal of Translational Medicine in 2018.

Further reading

Title
Author
Link
Type

Regeneus close to finalising first clinical partnership for its lead cell therapy in Japan

Tharun George

Web

Regeneus receives Chinese patent for biomarkers in monitoring disease progression for stem cell therapy

George Tchetvertakov

Web

Tim Boreham: What's next for stem cell play Regeneus as it waits for Japan deal

Tim Boreham

Web

Infobox
Is a
Company
Industry
Biotechnology
Location
England
Date incorporated
2007
Categories
Edits on 5 Feb, 2019
Baye Maniago"Approved suggestion from source: http://regeneus.com.au/"
Baye Maniago approved a suggestion from Golden's AI on 5 Feb, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Meredith Hanel
Meredith Hanel edited on 4 Feb, 2019
Edits made to:
Infobox (+4 properties)
Description (+217 characters)
Article (+1693 characters)
People (+5 rows) (+10 cells) (+170 characters)
Related Topics (+2 topics)
Topic thumbnail

Regeneus

An Australian clinical stage regenerative medicine company founded in 2007 developing cellular therapies based on stem cells and stem cell secretions to treat osteoarthritis, cancer, skin conditions and chronic pain.

Article

The company's allogeneic stem cell technology platform for the treatment of osteoarthritis (OA) and other inflammatory conditions is called Progenza. Results of the phase 1 STEP trial (Safety, Tolerability and Efficacy of Progenza) were published in the Journal of Translational Medicine in 2018.

The study showed that a single injection of Progenza, which are cells, into the knee was safe and well tolerated by patients the treatment was shown to have durable and clinically meaningful pain relief in patients with knee OA. A statistically significant improvement in lateral tibial cartilage volume for patients treated with 3.9 million cells of Progenza was shown by MRI compared to a worsening of the condition in placebo patients (p=0.028).

Progenza is an allogeneic off-the-shelf stem cell technology platform developed for the treatment of knee osteoarthritis and other inflammatory conditions. Progenza cells reduce inflammation and pain and encourage accelerated healing and repair through secretion of cytokines, growth factors and exosomes.

Progenza is produced from expanded mesenchymal stem cells (MSCs) extracted from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from MSCs that improve viability and functionality of the cells during the freezing and thawing process. Regeneus has shown that a combination of cells and secretions has a more powerful therapeutic effect than cells alone.

Progenza is manufactured using adipose-derived MSCs and are expanded through the company's proprietary and scalable manufacturing process which has the capacity to produce millions of therapeutic doses of Progenza from a single donor.

People

Name
Role
Related Golden topics

Dr Charlotte Morgan

Head of R&D

Dr Duncan Thomson

VP Licensing and Alliances

Janet Wilson

Clinical Research Director

John Bird

CFO

Professor Graham Vesey

Chief Scientific Officer

Infobox
Location
New South Wales
Related Topics
Meredith Hanel"Initial topic creation"
Meredith Hanel created this topic on 4 Feb, 2019
Edits made to:
Topic thumbnail

 Regeneus

An Australian clinical stage regenerative medicine company founded in 2007 developing cellular therapies based on stem cells and stem cell secretions to treat osteoarthritis, cancer, skin conditions and chronic pain.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.